INT166720

Context Info Confidence 0.36 First Reported 2008 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 3 Disease Relevance 0.84 Pain Relevance 1.13

nucleus (Rxrb)

Rxrb (Rattus norvegicus)

Pain Link Frequency Relevance Heat agonist 132 98.58 Inflammation 26 93.08 Potency 12 90.96 member 8 1 86.48 Inflammatory stimuli 4 80.64 cytokine 22 76.52 Arthritis 22 73.36 rheumatoid arthritis 36 57.76 anesthesia 2 24.80 ketamine 2 23.84

Disease Link Frequency Relevance Heat INFLAMMATION 32 93.08 Hypercalcemia 4 90.12 Osteoporosis 3 86.36 Experimental Arthritis 12 73.36 Arthritis 16 62.84 Rheumatoid Arthritis 38 57.76 Pressure And Volume Under Development 2 49.00 Disease 8 42.84 Osteoarthritis 2 37.84 Cancer 6 29.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

However, we also failed to demonstrate any potentiation of the suppressive effect of ATRA on IL-6 when it was used in combination with BMS-649, suggesting that activation of RXR played a minor role.

Positive_regulation (activation) of RXR associated with agonist

1) Confidence 0.36 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656246 Disease Relevance 0.17 Pain Relevance 0.65

First, we used compounds acting either on RAR or RXR, alone or in combination, to demonstrate that the downregulation of IL-6 was not dependent of RXR activation.

Positive_regulation (activation) of RXR

2) Confidence 0.36 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656246 Disease Relevance 0.35 Pain Relevance 0.40

This compound (VDRM2) potently induced Retinoid X Receptor alpha (RXR)-VDR heterodimerization (EC(50) = 7.1 +/- 1.6 nM) and induced osteocalcin promoter activity (EC(50) = 1.9 +/- 1.6 nM).

Positive_regulation (induced) of RXR

3) Confidence 0.14 Published 2010 Journal J. Bone Miner. Res. Section Abstract Doc Link 20200930 Disease Relevance 0.31 Pain Relevance 0.09

General Comments

This test has worked.